Loading organizations...
§ Private Profile · Boston, MA, USA
Outcomes4Me is a technology company.
Outcomes4Me provides an AI and machine learning-driven platform empowering cancer patients. The free platform delivers personalized, expert-validated treatment guidance, identifies relevant clinical trials, and suggests genetic testing based on a patient's diagnosis. This approach integrates established medical guidelines, such as the NCCN Clinical Practice Guidelines in Oncology.
Founded in 2017, Outcomes4Me was established by Dr. Maya Said, who serves as CEO. Said launched the company from the insight that cancer patients critically need accessible, personalized, and medically verified information to navigate treatment paths. Her healthcare and technology background informs this patient-empowerment approach.
The platform primarily serves cancer patients, equipping them with essential resources and evidence-based information for managing their disease. Outcomes4Me's core mission democratizes cancer care, ensuring every patient accesses comprehensive, reliable guidance to enhance treatment outcomes and overall well-being. The company envisions fundamentally improving the oncology patient experience.
Outcomes4Me has raised $42.7M across 4 funding rounds.
Outcomes4Me has raised $42.7M in total across 4 funding rounds.
Outcomes4Me has raised $42.7M across 4 funding rounds. Most recently, it raised $21.0M Series A in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $21M Series A | — | Asset Management Ventures, Breakthrough Energy Ventures, Darco Capital, Healthy Ventures, Northpond Ventures, SOSV, TET Ventures, Mark Cuban, Asset Management Ventures (amv), Forecast Labs, Hambro Perks, IRA Capital, AMY Summy, Merstal, Sierra Ventures | Announced |
| Apr 1, 2021 | $12M Series A | Northpond Ventures | Asset Management Ventures, Breakthrough Energy Ventures, Darco Capital, Healthy Ventures, SOSV, TET Ventures, Mark Cuban, Asset Management Ventures (amv), IRA Capital, Merstal, Sierra Ventures | Announced |
| Nov 18, 2020 | $4.7M Venture Round | Asset Management Ventures | Merstal, National Cancer Institute, Sierra Ventures | Announced |
| Nov 1, 2020 | $5M Seed | — | Asset Management Ventures, Healthy Ventures | Announced |
Outcomes4Me has raised $42.7M in total across 4 funding rounds.
Outcomes4Me's investors include Asset Management Ventures, Breakthrough Energy Ventures, Darco Capital, Healthy Ventures, Northpond Ventures, SOSV, Tet Ventures, Mark Cuban, Forecast Labs, Hambro Perks, IRA Capital, Amy Summy.
Outcomes4Me is an AI-driven patient empowerment platform that helps cancer patients navigate their care from diagnosis through treatment by providing personalized treatment options, clinical trial matching, genetic testing recommendations, symptom tracking, and real-time evidence-based clinical information.[1][2][4] The company serves cancer patients directly via a mobile app, while partnering with life sciences companies (including 8 of the top 10 global cancer pharmaceutical firms) to generate proprietary patient data for improved outcomes and research acceleration.[5][6] It solves the problem of fragmented, inaccessible healthcare information by democratizing access to NCCN Clinical Practice Guidelines, promoting health equity, and enabling proactive patient involvement, with strong growth since its 2022 commercial launch including doubled year-over-year revenue, over 400,000 global users, a $21M funding round, and 15+ industry awards.[2][3][5][6]
Founded in 2017 in Boston, Massachusetts, Outcomes4Me was started by Maya R. Said, Sc.D., a woman-led company comprising veterans from healthcare, oncology, pharmaceuticals, consumer tech, and technology.[1][2][4] Said's motivation stemmed from her personal experience as a patient, realizing the gap between her life sciences career assumptions and the real challenges patients face, prompting her to create a platform that empowers patients with their own health data and integrates NCCN Guidelines for the first time in a patient-facing format.[4] Early traction built through its patented AI technology, leading to commercial launch in 2022, rapid revenue growth, and key milestones like securing partnerships with top pharma companies and expanding to support over 280,000 patients by mid-2025.[3][6]
Outcomes4Me rides the wave of AI-personalized medicine and digital oncology, where data-driven care addresses rising cancer prevalence amid demands for patient-centric, equitable healthcare.[2][6] Its timing aligns with post-pandemic acceleration in telehealth, real-world evidence needs for pharma, and regulatory readiness (e.g., MDR certification via Mika), enabling faster European scaling in a $200B+ global oncology market.[3] Market forces like AI adoption in healthcare, pharma's shift to outcomes-based models, and patient empowerment trends favor it, as seen in its revenue trajectory and partnerships.[2][5][6] The company influences the ecosystem by generating proprietary datasets that fuel research, improve trial recruitment, and set standards for AI in direct-to-patient tools, bridging consumers, providers, and life sciences.[3][4]
Outcomes4Me is positioned for global dominance in digital cancer care, leveraging its $21M funding for international expansion (e.g., Europe via Mika) and AI enhancements to grow beyond 400,000 users toward millions.[3][6] Trends like multimodal AI agents, real-world data mandates, and precision oncology will propel it, potentially evolving into a full-stack platform for all chronic diseases while deepening pharma integrations for revenue diversification.[2][5] Its influence may expand by standardizing patient-generated data in research, tying back to its core mission of democratizing healthcare one empowered patient at a time.[4]